Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

Core Insights - Beacon Therapeutics has successfully raised over $75 million in an oversubscribed Series C financing round, led by Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund and existing investors [1][2][8] - The funds will be utilized to advance the development of laru-zova, a potential gene therapy for X-linked retinitis pigmentosa (XLRP), and to support the commercialization plans for this product [4][8] - The company is preparing for pivotal data on laru-zova expected in the second half of 2026, which is anticipated to be a significant milestone for the company [2][3] Company Overview - Beacon Therapeutics is a clinical-stage biotechnology company focused on saving and restoring vision for individuals with rare and prevalent ocular diseases, utilizing gene therapy to address severe ocular conditions [6] - The company's pipeline includes treatments for XLRP, geographic atrophy, and other inherited retinal diseases [4][6] Investor Insights - The Series C financing round included participation from notable investors such as Advent Life Sciences, Forbion, Oxford Science Enterprises, and Syncona Limited, indicating strong confidence in Beacon's mission [1][7] - Life Sciences at Goldman Sachs Alternatives, a new investor, aims to support the development of laru-zova and other pipeline candidates, highlighting the strategic partnership between the two entities [3][11] Market Context - XLRP affects over 100,000 patients in the US, with 14% estimated to have this specific condition, underscoring the potential impact of successful treatments in this area [3]